• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease.

作者信息

Ganesananthan Sashiananthan, Durai Dharmaraj

机构信息

Cardiff University School of Medicine, Cardiff, UK.

University Hospital Wales, Cardiff, UK.

出版信息

Clin Med (Lond). 2020 Mar;20(Suppl 2):s23-s24. doi: 10.7861/clinmed.20-2-s23.

DOI:10.7861/clinmed.20-2-s23
PMID:32409349
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7243528/
Abstract
摘要

相似文献

1
Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease.英夫利昔单抗治疗药物监测在成年炎症性肠病患者中的临床价值及成本节约情况
Clin Med (Lond). 2020 Mar;20(Suppl 2):s23-s24. doi: 10.7861/clinmed.20-2-s23.
2
Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings.炎症性肠病的治疗药物监测可减少不必要的英夫利昔单抗使用，并带来显著的相关成本节约。
Intern Med J. 2021 May;51(5):739-745. doi: 10.1111/imj.14644.
3
Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.英夫利昔单抗治疗药物监测在炎症性肠病的虚拟生物制剂临床中改变了临床决策。
Inflamm Bowel Dis. 2017 Dec;23(12):2083-2088. doi: 10.1097/MIB.0000000000001258.
4
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.治疗药物监测在炎症性肠病中对抗肿瘤坏死因子治疗应答丧失的管理中比基于临床的方法更具成本效益：一项观察性多中心研究。
J Crohns Colitis. 2018 Aug 29;12(9):1079-1088. doi: 10.1093/ecco-jcc/jjy076.
5
Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.比较英夫利昔单抗和阿达木单抗治疗炎症性肠病的药物生存情况。
Int J Clin Pharm. 2020 Apr;42(2):500-507. doi: 10.1007/s11096-020-00978-6. Epub 2020 Jan 31.
6
Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to Conclude.皮下注射英夫利昔单抗的治疗药物监测？结论尚早。
Clin Gastroenterol Hepatol. 2023 Aug;21(9):2193-2194. doi: 10.1016/j.cgh.2022.12.028. Epub 2023 Jan 5.
7
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.慢性免疫介导性炎症疾病患者英夫利昔单抗诱导治疗期间的治疗药物监测与标准治疗——回复
JAMA. 2021 Sep 21;326(11):1069-1070. doi: 10.1001/jama.2021.11480.
8
Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.在活动性炎症性肠病中，与仅依靠临床决策相比，通过治疗药物监测来指导英夫利昔单抗剂量调整与更好的内镜检查结果相关。
Inflamm Bowel Dis. 2017 Jul;23(7):1202-1209. doi: 10.1097/MIB.0000000000001126.
9
INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE.英夫利昔单抗诱导治疗药物监测方案：炎症性肠病简化的基于证据的算法。
Arq Gastroenterol. 2020 Oct-Dec;57(4):507-510. doi: 10.1590/S0004-2803.202000000-76.
10
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.英夫利昔单抗维持治疗期间治疗药物监测与标准疗法及免疫介导炎症性疾病的控制
JAMA. 2022 Apr 19;327(15):1506. doi: 10.1001/jama.2022.2932.

引用本文的文献

1
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.治疗药物监测中的挑战：优化炎症性肠病和其他免疫介导的炎症性疾病患者的生物治疗。
Ther Drug Monit. 2023 Oct 1;45(5):579-590. doi: 10.1097/FTD.0000000000001095. Epub 2023 Apr 3.
2
Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review.炎症性肠病中抗TNF治疗药物监测的成本效益：一项系统评价
Pharmaceutics. 2022 May 7;14(5):1009. doi: 10.3390/pharmaceutics14051009.
3
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.皮下注射英夫利昔单抗治疗风湿性疾病和炎症性肠病的观点：COVID-19 时代之前、期间和之后。
Adv Ther. 2022 Jun;39(6):2342-2364. doi: 10.1007/s12325-021-01990-6. Epub 2022 Jan 6.

本文引用的文献

1
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.美国胃肠病学会关于炎症性肠病治疗药物监测的学会指南。
Gastroenterology. 2017 Sep;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032. Epub 2017 Aug 3.
2
Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.通过监测药物水平和抗药抗体优化炎症性肠病中肿瘤坏死因子抑制剂的治疗
Inflamm Bowel Dis. 2016 Aug;22(8):1999-2015. doi: 10.1097/MIB.0000000000000772.
3
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.系统评价：预测和优化克罗恩病抗TNF治疗反应——实用管理算法
Aliment Pharmacol Ther. 2016 Jan;43(1):30-51. doi: 10.1111/apt.13445. Epub 2015 Oct 30.
4
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.根据英夫利昔单抗的血药浓度指导炎症性肠病患者的给药剂量。
Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24.